Pfizer’s coronavirus vaccine is more than 90 percent effective in first analysis, company reports

by

Pfizer and its German partner, BioNTech, say they will apply for emergency authorization from regulators after the third week of November.

View original article
Contributor: Carolyn Y. Johnson